Show simple item record

Pharmacodynamic effect of IMCgp100 (TCR CD3 bispecific) on peripheral cytokines and association with overall survival in patients with advanced melanoma

dc.contributor.authorMiddleton, MR
dc.contributor.authorSteven, NM
dc.contributor.authorEvans, TRJ
dc.contributor.authorInfante, JR
dc.contributor.authorHamid, O
dc.contributor.authorShoushtari, AN
dc.contributor.authorCorrie, PG
dc.contributor.authorAnthoney, A
dc.contributor.authorGupta, Avinash
dc.contributor.authorWoodcock, VK
dc.contributor.authorMcAlpine, C
dc.contributor.authorSznol, M
dc.date.accessioned2019-11-19T16:01:07Z
dc.date.available2019-11-19T16:01:07Z
dc.date.issued2019en
dc.identifier.citationMiddleton MR, Steven NM, Evans TRJ, Infante JR, Hamid O, Shoushtari AN, et al. Pharmacodynamic effect of IMCgp100 (TCR�CD3 bispecific) on peripheral cytokines and association with overall survival in patients with advanced melanoma. J Clin Oncol. 2019;37(15_suppl):9523-.en
dc.identifier.doi10.1200/JCO.2019.37.15_suppl.9523en
dc.identifier.urihttp://hdl.handle.net/10541/622458
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2019.37.15_suppl.9523en
dc.titlePharmacodynamic effect of IMCgp100 (TCR CD3 bispecific) on peripheral cytokines and association with overall survival in patients with advanced melanomaen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentChurchill Hospital, Oxforden
dc.identifier.journalJournal of Clinical Oncologyen


This item appears in the following Collection(s)

Show simple item record